MDMB-FUBICA

Chemical compound From Wikipedia, the free encyclopedia

MDMB-FUBICA is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug.[1]

Legal status
Quick facts Legal status, Identifiers ...
MDMB-FUBICA
Legal status
Legal status
Identifiers
  • methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indol-3-yl}formamido)-3,3-dimethylbutanoate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC23H25FN2O3
Molar mass396.462 g·mol−1
3D model (JSmol)
  • COC(=O)[C@@H](NC(=O)c1cn(Cc2ccc(F)cc2)c3ccccc13)C(C)(C)C
  • InChI=1S/C23H25FN2O3/c1-23(2,3)20(22(28)29-4)25-21(27)18-14-26(19-8-6-5-7-17(18)19)13-15-9-11-16(24)12-10-15/h5-12,14,20H,13H2,1-4H3,(H,25,27)/t20-/m1/s1
  • Key:RVAWIZIGOSKPBP-HXUWFJFHSA-N
Close

It was first detected by the EMCDDA in Sweden in February 2015.[2] It is often sold in e-liquid form for use in an electronic cigarette.[3]

Side effects

MDMB-FUBICA's indazole analogue MDMB-FUBINACA has been linked to at least 1000 hospitalisations and 40 deaths as a consequence of intoxication as of March 2015.[4]

Legality

MDMB-FUBICA is banned in Sweden.[5]

See also

References

Related Articles

Wikiwand AI